IN2014DN07897A - - Google Patents

Info

Publication number
IN2014DN07897A
IN2014DN07897A IN7897DEN2014A IN2014DN07897A IN 2014DN07897 A IN2014DN07897 A IN 2014DN07897A IN 7897DEN2014 A IN7897DEN2014 A IN 7897DEN2014A IN 2014DN07897 A IN2014DN07897 A IN 2014DN07897A
Authority
IN
India
Prior art keywords
pharmaceutical composition
controued
gliclazide
stabilized
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Ravindra Agarwal
Ajay Kumar Dobhal
Ravi Kochhar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN7897DEN2014 priority Critical patent/IN2014DN07897A/en
Publication of IN2014DN07897A publication Critical patent/IN2014DN07897A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2001/00—Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as moulding material
    • B29K2001/08—Cellulose derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0044—Stabilisers, e.g. against oxydation, light or heat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN7897DEN2014 2012-02-24 2013-02-23 IN2014DN07897A (ar)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN7897DEN2014 IN2014DN07897A (ar) 2012-02-24 2013-02-23

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN538DE2012 2012-02-24
IN7897DEN2014 IN2014DN07897A (ar) 2012-02-24 2013-02-23
PCT/IB2013/051467 WO2013124832A2 (en) 2012-02-24 2013-02-23 Stabilized controlled-release pharmaceutical composition comprising gliclazide

Publications (1)

Publication Number Publication Date
IN2014DN07897A true IN2014DN07897A (ar) 2015-04-24

Family

ID=49006330

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7897DEN2014 IN2014DN07897A (ar) 2012-02-24 2013-02-23

Country Status (4)

Country Link
US (1) US20150031737A1 (ar)
CA (1) CA2865484A1 (ar)
IN (1) IN2014DN07897A (ar)
WO (1) WO2013124832A2 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777207A (zh) * 2021-09-09 2021-12-10 安徽省食品药品检验研究院(安徽国家农副加工食品质量监督检验中心) 一种格列齐特缓释片溶出曲线的测定方法、相似性评价方法及其应用
CN115598267B (zh) * 2022-12-13 2023-05-09 山东省食品药品检验研究院 一种格列齐特中潜在遗传毒性杂质的分析方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156343A (en) * 1994-12-27 2000-12-05 Akzo Nobel N.V. Controlled release preparation
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide

Also Published As

Publication number Publication date
CA2865484A1 (en) 2013-08-29
US20150031737A1 (en) 2015-01-29
WO2013124832A3 (en) 2013-11-07
WO2013124832A2 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
TN2015000278A1 (en) Autotaxin inhibitors
GB201118656D0 (en) New compounds
MD20150091A2 (ro) Compuşi antivirali
IN2014MN00986A (ar)
GB201209613D0 (en) New compounds
MX349004B (es) Nuevos compuestos.
PH12015501609A1 (en) Phenicol antibacterials
PH12015501096A1 (en) Composition for immediate and extended release
GEP201706621B (en) Benzamides
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
EP2931310A4 (en) COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
IN2014DN03010A (ar)
IN2014DN07897A (ar)
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
IN2012DE00826A (ar)
IN2013CH04314A (ar)
IN2013MU03317A (ar)
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2014DN10683A (ar)
IN2013CH04330A (ar)